Literature DB >> 18045753

Declining prevalence of hepatitis B virus infection in Catalonia (Spain) 12 years after the introduction of universal vaccination.

L Salleras1, A Domínguez, M Bruguera, P Plans, J Costa, N Cardeñosa, J Batalla, A Plasència.   

Abstract

AIMS: To analyze the prevalence of hepatitis B virus infection markers and hepatitis B vaccination in a representative sample of the juvenile and adult population of Catalonia and to evaluate the changes with respect to seroepidemiological surveys carried out in 1989 and 1996.
DESIGN: In all subjects anti-HBc and anti-HBs antibodies and HBsAg were determined using an ELISA test. The possible association between sociodemographic variables and the prevalence of markers was analysed by calculating the adjusted odd ratio (simple logistic regression).
SETTING: The study was carried out in 2002 in representative samples of the juvenile (5-14 years) and adult population (>or= 15 years) of Catalonia (Spain). MAIN
RESULTS: In 2002 the global prevalence of HBsAg+ was 0.7% (95% CI: 0.4-1.0) and that of anti-HBc+ 8.7% (95% CI: 7.6-9.8), values higher than those obtained in 1989 of 1.5% (95% CI: 1.0-2.1) and 15.6 (95% CI: 13.9-17.3). The prevalence of markers of infection increased with age. The only sociodemographic variable significantly associated with the prevalence of hepatitis B virus infection was the place of birth. The risk of infection was twice as high in subjects born outside Catalonia (p<0.01), adjusted OR 2.0 (95% CI: 1.34-2.98) compared with those born in Catalonia.
CONCLUSIONS: The results of this study show that the prevalence of hepatitis B virus infection (anti-HBc+) in Catalonia (Spain) is currently the lowest it has ever been and suggest that there has been a change in the pattern of endemicity of hepatitis B virus infection in Catalonia, which has become a country of low endemicity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18045753     DOI: 10.1016/j.vaccine.2007.10.027

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Serological survey of hepatitis B immunity in healthcare workers in Catalonia (Spain).

Authors:  A Domínguez; L Urbiztondo; J M Bayas; E Borrás; S Broner; M Campins; J Costa; M Esteve
Journal:  Hum Vaccin Immunother       Date:  2016-12-27       Impact factor: 3.452

2.  Current trends in access to treatment for hepatitis B in immigrants vs non-immigrants.

Authors:  Mireia Miquel; Albert Pardo; Montse Forné; Gemma Martínez-Alpin; Adrià Rodríguez-Castellano; Meritxell Casas; Mercè Rosinach; Mercè Roget; Blai Dalmau; Rocío Temiño; Joan Carlos Quer; Jordi Sanchez-Delgado; Jordi Ortiz; Mercedes Vergara
Journal:  Gastroenterol Rep (Oxf)       Date:  2020-03-27

Review 3.  Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.

Authors:  Claus Niederau
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

Review 4.  Diagnosis of Liver Involvement in Primary Sjögren Syndrome.

Authors:  Pilar Brito Zeron; Soledad Retamozo; Albert Bové; Belchin Adriyanov Kostov; Antoni Sisó; Manuel Ramos-Casals
Journal:  J Clin Transl Hepatol       Date:  2013-12-15

Review 5.  Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM).

Authors:  Maria Gonzalez-Cao; Teresa Puertolas; Mar Riveiro; Eva Muñoz-Couselo; Carolina Ortiz; Roger Paredes; Daniel Podzamczer; Jose Luis Manzano; Jose Molto; Boris Revollo; Cristina Carrera; Lourdes Mateu; Sara Fancelli; Enrique Espinosa; Bonaventura Clotet; Javier Martinez-Picado; Pablo Cerezuela; Ainara Soria; Ivan Marquez; Mario Mandala; Alfonso Berrocal
Journal:  J Immunother Cancer       Date:  2021-03       Impact factor: 13.751

Review 6.  Diagnosis and treatment of hepatitis B. What contributions can prisons make?

Authors:  M Vergara
Journal:  Rev Esp Sanid Penit       Date:  2021 Sep-Dec

Review 7.  Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening.

Authors:  Susan J M Hahné; Irene K Veldhuijzen; Lucas Wiessing; Tek-Ang Lim; Mika Salminen; Marita van de Laar
Journal:  BMC Infect Dis       Date:  2013-04-18       Impact factor: 3.090

8.  Prevalence and risk factors of hepatitis B virus infection in Bahrain, 2000 through 2010.

Authors:  Essam M Janahi
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

9.  Prevalence of hepatitis B virus seromarkers in young adults vaccinated at birth; impact on the epidemiology of hepatitis B infection in iran.

Authors:  Hiva Saffar; Abolghasem Ajami; Mohammed Jafar Saffar; Jalil Shojaei; Maryam Sotudeh-Anvari; Kiarash Shams-Esfandabad; Ali Reza Khalilian
Journal:  Hepat Mon       Date:  2014-05-01       Impact factor: 0.660

10.  The effectiveness of the national hepatitis B vaccination program 25 years after its introduction in Iran: a historical cohort study.

Authors:  Mohsen Moghadami; Nazanin Dadashpour; Ali Mohammad Mokhtari; Mostafa Ebrahimi; Alireza Mirahmadizadeh
Journal:  Braz J Infect Dis       Date:  2019-11-01       Impact factor: 3.257

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.